This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Discussion on the recent FDA approval in the US for the first CD20xCD3 bispecific antibody(mosunetuzumab) in adult patients with relapsed or refractory follicular lymphoma

Ticker(s): RHHBY

Who's the expert?

Institution: Cochise Oncology

  • Hematologist/Oncology specialist and a Hematologist in Garden City, Michigan. 
  • Goldfarb has been practicing medicine for over 52 years and is highly rated in 14 conditions
  •  Top areas of expertise are Lung Cancer, Paget Disease of the Breast, Lung Adenocarcinoma, and Small Cell Lung Cancer SCLC. 
  • Manages 14 patients with multiple myeloma and currently prescribes tecvayil

Interview Goal
.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.